Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04314752 · ClinicalTrials.gov registry record

Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities

A clinical trial of Multiple Myeloma, sponsored by University of California, Davis.

Recruiting
Registry status
4,000
Enrollment target
1
Study location

NCT04314752: Recruiting study of Multiple Myeloma, sponsored by University of California, Davis.

NCT04314752 is a study of Multiple Myeloma that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 4,000 participants, above the 538-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (643% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04314752, a study of Multiple Myeloma, is actively recruiting participants, sponsored by University of California, Davis.

RECRUITING
Registry status
4,000 participants
Enrollment target
1
Study location

Study Summary

The objectives of the proposed study are to develop and evaluate protocols for ethnic/racial minority-specific research using cancer registry data. In conjunction with the Cancer Registry of Greater California (CRGC), the investigators have developed procedures to identify, recruit, and survey ethnic/racial minority patients with MM. To pilot the study, the investigators aim initially to test the feasibility of this protocol by contacting 400 eligible patients (100 African Americans, 100 Latinos, 100 Asian American/Native Hawaiian/Pacific Islander-AANHPI and 100 non-Hispanic Whites as a comparison group) to conduct a pilot survey through which will ascertain etiological and survival-related factors for MM. Ultimately, the investigators hope the findings from this pilot will yield insight into the best practices for recruiting minorities with MM and serve as the basis for larger population-based studies of MM etiology and survival. The next phase of this study is to expand the study to all 3 California Cancer Registries, including the Greater Bay Area Cancer Registry and the Los Angeles Cancer Surveillance Program and Cancer Registry of Greater California. We will increase the sample size to recruit atleast 1000 participants per racial/ethnic group. We will also request to increase the scope of the study to also continue a survivorship cohort.

Primary Outcome

Response Rate in percentage

Conditions Studied

Study Locations (1)

California

  • University of California Davis Comprehensive Cancer Center - Sacramento

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2020-09-01
Est. Completion 2026-05-30
University of California, Davis

657 total trials

What NCT04314752 shows while recruiting

NCT04314752 is an observational study that tracks outcomes without assigning an intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 538-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (643% higher).

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.

NCT04314752 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04314752 about?

NCT04314752 is a clinical study titled "Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities". The objectives of the proposed study are to develop and evaluate protocols for ethnic/racial minority-specific research using cancer registry data. In conjunction with the Cancer Registry of Greater California (CRGC), the investigators have developed procedures to identify, recruit, and survey ethni...

What is the current status of trial NCT04314752?

This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2020-09-01. Estimated completion is 2026-05-30.

What conditions does trial NCT04314752 study?

This clinical trial studies the following conditions: Multiple Myeloma.

Who is sponsoring clinical trial NCT04314752?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04314752 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04314752's enrollment target sits among peer trials

4,000 9th of 438 higher than 430 of 438 other Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00227253 · 4,000 participants

    Chromosome 18 Clinical Research Center

  • NCT00811148 · 4,000 participants

    Florida Center for Brain Tumor Research

  • NCT00897117 · 4,000 participants

    Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

  • NCT00899301 · 4,000 participants

    Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04314752, the US trial registry maintained by the National Library of Medicine. NCT04314752 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.